CureVac COVID vaccine let-down spotlights mRNA design challenges.

@article{Dolgin2021CureVacCV,
  title={CureVac COVID vaccine let-down spotlights mRNA design challenges.},
  author={Elie S. Dolgin},
  journal={Nature},
  year={2021}
}
  • E. Dolgin
  • Published 18 June 2021
  • Medicine
  • Nature
View on PubMed
nature.com
38 Citations
Highly Influential Citations
1
Background Citations
13
Methods Citations
2
Results Citations
4

38 Citations

mRNA-based modalities for infectious disease management

The unique properties of mRNA-based vaccines for infectious diseases, delivery technologies, discussed current challenges, and highlighted the prospects of this promising technology in the future are summarized.

mRNA vaccines against COVID‐19: a showcase for the importance of microbial biotechnology

The modest protection achieved with a similarly designed mRNA from CureVac underlines the importance of biotechnological details in formulation such as replacement of uridine by pseudouridine in the mRNA encoding the SARS‐CoV‐2 spike protein or the lipid composition of the nanoparticle coating the mRNA.

Messenger ribonucleic acid vaccines for severe acute respiratory syndrome coronavirus-2 – a review

The Importance of RNA-Based Vaccines in the Fight against COVID-19: An Overview

This review emphasizes mRNA and self-amplifying RNA (saRNA) for vaccine development, mainly to fight against COVID-19, together with the challenges related to this approach.

The Critical Contribution of Pseudouridine to mRNA COVID-19 Vaccines

The clinical trial efficacy results of the Curevac mRNA vaccine (CVnCoV) suggested that the delivery system was not the only key to the success, and here the authors highlight the features of N1-methyl-pseudouridine and its contributions to mRNA vaccines.

An overview of current drugs and prophylactic vaccines for coronavirus disease 2019 (COVID-19)

In this review, currently authorized COVID-19 vaccines as well as variants of the virus are described and evaluated, considering all platforms.

Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action

The relevance of structural modifications of S in different vaccines and the different modes of antigen expression after vaccination with genetic adenovirus-vector and mRNA vaccines are reviewed.

Analyzing the Systems Biology Effects of COVID-19 mRNA Vaccines to Assess Their Safety and Putative Side Effects

The approach has identified mechanisms underlying both the expected protective effects of vaccination as well as possible post-vaccine adverse effects, and illustrates the power of systems biology approaches in improving the understanding of the comprehensive biological response to vaccination against COVID-19.

Design Optimization and Immune Kinetics of mRNA Vaccines

The critical impact of noncoding region optimization on vaccine efficacy as well as mRNA vaccines’ capability for rapid immune kinetics is established.

Accelerated COVID-19 vaccine development: milestones, lessons, and prospects

References

SHOWING 1-2 OF 2 REFERENCES

Phase 1 Assessment of the Safety and Immunogenicity of an mRNA- Lipid Nanoparticle Vaccine Candidate Against SARS-CoV-2 in Human Volunteers

Preliminary results in the subset of subjects who were enrolled with known SARS-CoV-2 seropositivity at baseline show that CVnCoV is also safe and well tolerated in this population, and is able to boost the pre-existing immune response even at low dose levels.

Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA.